Rett
58 programs · 57 companies
Programs
58
Companies
57
Trials
56
MOAs
37
KRASG12DiSGLT2iSOS1iUSP1iIL-17iALKiMDM2iTROP-2 ADCRAS(ON)iIL-23i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanusertib | Approved | PCSK9 | ||
| BAY-3308 | Phase 1 | ALK | ||
| REG-647 | Preclinical | SMN2 | ||
| Datozumab | Phase 1 | B7-H3 | ||
| Elrarapivir | NDA/BLA | PRMT5 | ||
| Nidasacituzumab | Phase 1/2 | TIM-3 | ||
| Rimasertib | Phase 3 | B7-H3 | ||
| Mavuzasiran | Phase 3 | MET | ||
| Adagralucimab | NDA/BLA | CD123 | ||
| Miriderotide | NDA/BLA | MDM2 | ||
| Teraratamab | Preclinical | CD3 | ||
| Gelirelsin | Phase 2 | KIF18A | ||
| QUO-7972 | NDA/BLA | BCMA | ||
| VIG-6767 | Phase 2/3 | CD47 | ||
| Darazasiran | Phase 3 | B7-H3 | ||
| Datolucimab | Approved | EZH2 | ||
| Talacapivasertib | Phase 1/2 | SOS1 | ||
| CN-9071 | Preclinical | WRN | ||
| LUC-2815 | Phase 1 | PCSK9 | ||
| Mavucagene | Phase 1/2 | VEGF | ||
| Doxasotorasib | Phase 1/2 | PD-L1 | ||
| Teratapinarof | Phase 3 | USP1 | ||
| KNS-1946 | Phase 3 | DLL3 | ||
| Kemanesiran | Phase 1 | GLP-1R | ||
| Bemaosocimab | Phase 3 | IL-17A | ||
| Zoribrutinib | Phase 2/3 | WRN | ||
| Tezecapivasertib | Phase 1/2 | KRASG12D | ||
| Polatinib | Phase 2 | Tau | ||
| Rilunaritide | Approved | Cl18.2 | ||
| SEN-1840 | Phase 2 | BET | ||
| Ribotapinarof | NDA/BLA | MET | ||
| Talarelsin | Phase 3 | KIF18A | ||
| SRR-6281 | Phase 1/2 | RET | ||
| Pexaderotide | NDA/BLA | GIP-R | ||
| Niratenlimab | Phase 1 | USP1 | ||
| PHM-5291 | Phase 3 | BCMA | ||
| Gelitenlimab | Phase 1/2 | BTK | ||
| PCI-4776 | Phase 3 | PSMA | ||
| PHO-7143 | Phase 2/3 | PD-L1 | ||
| PAC-8776 | Preclinical | TYK2 | ||
| Bemacilimab | NDA/BLA | WEE1 | ||
| BPT-5103 | Phase 2 | PSMA | ||
| 415-7241 | Phase 1 | HER2 | ||
| Semafutibatinib | Phase 3 | Nectin-4 | ||
| HYP-6990 | Preclinical | PI3Kα | ||
| APN-7734 | Phase 1 | CDK4/6 | ||
| ASP-8596 | Phase 2 | CD123 | ||
| IRC-IIT-214 | Phase 2 | CD47 | ||
| SIR-IIT-898 | Phase 3 | MALT1 | ||
| BEA-1452 | Phase 1 | CDK4/6 | ||
| Motanesiran | Phase 2/3 | MDM2 | ||
| Rimamavacamten | Preclinical | GPRC5D | ||
| Doxatenlimab | Phase 2 | KRASG12C | ||
| KRK-8556 | Phase 1 | KIF18A | ||
| ZEN-8892 | Phase 2/3 | SOS1 | ||
| GR-8075 | Preclinical | KRASG12C | ||
| DNA-3921 | NDA/BLA | AHR | ||
| 115-7101 | Phase 1 | SGLT2 |
Trials (56)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT05987952 | REG-647 | Preclinical | Active |
| NCT07306036 | Elrarapivir | NDA/BLA | Completed |
| NCT07966612 | Elrarapivir | NDA/BLA | Active |
| NCT04537675 | Rimasertib | Phase 3 | Terminated |
| NCT07776640 | Mavuzasiran | Phase 3 | Recruiting |
| NCT05100075 | Mavuzasiran | Phase 3 | Active |
| NCT08850554 | Mavuzasiran | Phase 3 | Completed |
| NCT08640596 | Mavuzasiran | Phase 3 | Completed |
| NCT06733075 | Miriderotide | NDA/BLA | Terminated |
| NCT03546131 | Miriderotide | NDA/BLA | Completed |
| NCT04209027 | Teraratamab | Preclinical | Recruiting |
| NCT07200387 | Teraratamab | Preclinical | Recruiting |
| NCT03200111 | Gelirelsin | Phase 2 | Recruiting |
| NCT03849130 | VIG-6767 | Phase 2/3 | Active |
| NCT07051515 | Darazasiran | Phase 3 | Terminated |
| NCT04962343 | Datolucimab | Approved | Terminated |
| NCT07712666 | Datolucimab | Approved | Terminated |
| NCT04770434 | Datolucimab | Approved | Not yet recr... |
| NCT04944188 | CN-9071 | Preclinical | Recruiting |
| NCT07184721 | Mavucagene | Phase 1/2 | Recruiting |